Valuation: Ultragenyx Pharmaceutical Inc.

Market Cap 3.52B 3.09B 2.85B 2.64B 5B 337B 5.1B 34.29B 13.32B 165B 13.23B 12.94B 573B P/E 2026 *
-7.93x
P/E 2027 * -46.4x
Enterprise Value 3.04B 2.67B 2.47B 2.28B 4.32B 291B 4.4B 29.63B 11.51B 143B 11.43B 11.18B 495B EV / Sales 2026 *
4.11x
EV / Sales 2027 * 3.06x
Free-Float
96.25%
Yield 2026 *
-
Yield 2027 * -
1 day-3.36%
1 week+6.95%
Current month+3.71%
1 month+60.40%
3 months+49.59%
6 months+49.20%
Current year+50.57%
1 week 32.48
Extreme 32.48
36.57
1 month 22.03
Extreme 22.03
36.57
Current year 18.29
Extreme 18.29
36.57
1 year 18.29
Extreme 18.29
42.37
3 years 18.29
Extreme 18.29
60.37
5 years 18.29
Extreme 18.29
104.38
10 years 18.29
Extreme 18.29
179.65
Manager TitleAgeSince
Chief Executive Officer 65 2010-04-21
Director of Finance/CFO 49 2023-10-15
Chief Tech/Sci/R&D Officer 53 2023-04-30
Director TitleAgeSince
Director/Board Member 65 2010-04-21
Director/Board Member 61 2013-12-31
Director/Board Member 66 2015-02-19
Date Insider Type Main position Quantity % Market Cap.
06-30Sell

Chief Financial Officer

-4,698 0.0048%
06-14Sell

Director

-2,000 0.0020%
06-14Sell

General Counsel

-1,899 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
-3.33%+6.95%-12.15%-21.56% 3.52B
+1.54%+10.14%+5.34%-81.69% 2.09B
-1.28%+1.21%-9.78%-6.68% 312M
-3.23%-2.83%-45.64% - 52.37M
Average -1.56%+3.74%-15.56%-36.65% 1.49B
Weighted average by Cap. -1.51%+7.91%-6.21%-41.99%

Financials

2026 *2027 *
Net sales 741M 650M 600M 555M 1.05B 70.99B 1.07B 7.22B 2.8B 34.74B 2.78B 2.72B 121B 984M 863M 797M 737M 1.4B 94.25B 1.42B 9.58B 3.72B 46.12B 3.7B 3.62B 160B
Net income -475M -417M -385M -356M -674M -45.52B -688M -4.63B -1.8B -22.28B -1.79B -1.75B -77.33B -88.64M -77.74M -71.77M -66.33M -126M -8.49B -128M -863M -335M -4.15B -333M -326M -14.42B
Net Debt -478M -419M -387M -358M -678M -45.75B -691M -4.65B -1.81B -22.39B -1.79B -1.75B -77.72B -508M -446M -412M -380M -721M -48.68B -736M -4.95B -1.92B -23.82B -1.91B -1.87B -82.7B
Logo Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.
Employees
1,371
Date Price Change Volume
26-07-08 US$34.77 -3.07% 1,369,015
26-07-07 US$35.87 +6.44% 4,421,797
26-07-06 US$33.70 +0.69% 1,553,103
26-07-02 US$33.47 +3.37% 1,239,269
26-07-01 US$32.38 -3.02% 2,635,814
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
35.87USD
Average target price
52.32USD
Spread / Average Target
+45.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RARE Stock